• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ocugen Inc. filed SEC Form 8-K: Leadership Update

    6/3/26 4:30:32 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email
    false 0001372299 0001372299 2026-05-29 2026-05-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 29, 2026

     

    OCUGEN, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36751   04-3522315
    (State or other jurisdiction
    of incorporation)
      (Commission File
    Number)
      (IRS Employer
    Identification No.)

     

    11 Great Valley Parkway

    Malvern, Pennsylvania

      19355
    (Address of principal executive offices)   (Zip Code)

     

    (484) 328-4701

    Registrant’s telephone number, including area code: 

     

    N/A

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Stock, par value $0.01 per share   OCGN  

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. (the “Company”). Following the resignation of Mr. Ramachandran, who was designated as the Company's principal accounting officer prior to his resignation, on June 3, 2026, Rita Johnson-Greene, MBA, the Company’s Chief Financial Officer, was appointed as the Company’s principal accounting officer.

     

    Descriptions of the material terms of Ms. Johnson-Greene’s employment agreement and Ms. Johnson-Greene’s biographical information were previously included in the Company’s Current Report on Form 8-K filed on February 9, 2026, which descriptions are incorporated herein by reference. There are no arrangements or understandings between Ms. Johnson-Greene and any other persons pursuant to which Ms. Johnson-Greene was appointed as principal accounting officer of the Company. In addition, there are no family relationships between Ms. Johnson-Greene and any director or executive officer of the Company, and there are no transactions involving Ms. Johnson-Greene requiring disclosure under Item 404(a) of Regulation S-K.

     

    1 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        OCUGEN, INC.
         
    Date: June 3, 2026 By: /s/ Shankar Musunuri
        Name: Shankar Musunuri
        Title: Chairman, Chief Executive Officer, & Co-Founder

     

    2 

     

    Get the next $OCGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    3/17/2026$12.00Buy
    Canaccord Genuity
    3/11/2026$10.00Outperform
    Oppenheimer
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group initiated coverage on Ocugen with a new price target

    Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

    10/15/24 8:07:55 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocugen to Participate in Upcoming June Investor and Industry Conferences

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026. Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference Date: Thursday, June 4, 2026 Time: 2:30pm EDT Clinical Trials at the Summit 2026 Location: Fontainebleau Las VegasDate: Saturday, June 13, 2026Time: 10:19 – 10:39 am PDTInherited Retinal Diseases: Transforming the Future Through InnovationModerator: Peter KaiserPanelists: Lance Baldo, Pau

    6/2/26 7:03:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

    MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), including the full exercise by the initial purchaser of its option to purchase an additional $15.0 million aggregate principal amount of the notes. The sale of the notes is expected to result in approximately $112.6 million in ne

    5/14/26 4:30:00 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Participate in Upcoming May Scientific and Investor Conferences

    MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026. Retina World Congress Inherited and Rare Retinal Diseases SessionModerators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRSLocation: Grand BallroomDate: Thursday, May 14, 2026Time: 10:31 am – 11:10 a.m. EDT Stifel 2026 Virtual Ophthalmology Forum Location: VirtualDate: Tuesday, May 26, 2026 Time: 10:30 am – 10:55 a.m. EDT A webcast of the Stife

    5/13/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Zhang Junge

    4 - Ocugen, Inc. (0001372299) (Issuer)

    4/2/26 9:26:46 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Johnson-Greene Treerita Essalima claimed ownership of 500,350 shares (SEC Form 3)

    3 - Ocugen, Inc. (0001372299) (Issuer)

    3/5/26 9:27:38 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Musunuri Shankar was granted 3,123,201 shares, increasing direct ownership by 170% to 4,955,924 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    1/6/26 5:20:32 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    SEC Filings

    View All

    Ocugen Inc. filed SEC Form 8-K: Leadership Update

    8-K - Ocugen, Inc. (0001372299) (Filer)

    6/3/26 4:30:32 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - Ocugen, Inc. (0001372299) (Filer)

    5/14/26 4:31:51 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    5/14/26 4:30:23 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Financials

    Live finance-specific insights

    View All

    Ocugen Provides Business Update with First Quarter 2026 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in lesion size and 27% EZ preservation (correlated to visual function) in optimal dose for Phase 3 About 20% of patients demonstrated no progression of disease and 75% of subjects showed > 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profileAllows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95% Trial enrollment complete for OCU400 for retinitis p

    5/5/26 8:32:54 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

    MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 4973685Webcast: Available on the events section of the Ocugen

    4/29/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

    MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu

    3/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

    MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes

    9/9/24 6:30:12 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

    MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting

    5/28/24 7:02:39 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/4/24 1:43:41 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Ocugen Inc.

    SC 13G - Ocugen, Inc. (0001372299) (Subject)

    10/16/24 12:41:30 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care